A61K 47/54
The modifying agent being an organic compound
Official title: the modifying agent being an organic compound
A61K47/54 (The modifying agent being an organic compound) appears on 6,277 US grants and 11,248 published applications in this corpus.
Search patents in A61K- Granted patents
- 6,277
- Published applications
- 11,248
- Assignees
- 3,546
- Inventors
- 18,882
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 6 | 0 |
| 1983 | 2 | 0 |
| 1984 | 4 | 0 |
| 1985 | 3 | 0 |
| 1986 | 7 | 0 |
| 1987 | 3 | 0 |
| 1988 | 10 | 0 |
| 1989 | 19 | 0 |
| 1990 | 16 | 0 |
| 1991 | 17 | 0 |
| 1992 | 28 | 0 |
| 1993 | 29 | 0 |
| 1994 | 26 | 0 |
| 1995 | 40 | 0 |
| 1996 | 58 | 0 |
| 1997 | 77 | 0 |
| 1998 | 113 | 0 |
| 1999 | 98 | 0 |
| 2000 | 90 | 0 |
| 2001 | 63 | 22 |
| 2002 | 93 | 117 |
| 2003 | 69 | 202 |
| 2004 | 72 | 195 |
| 2005 | 48 | 201 |
| 2006 | 117 | 198 |
| 2007 | 65 | 173 |
| 2008 | 73 | 172 |
| 2009 | 80 | 226 |
| 2010 | 96 | 259 |
| 2011 | 100 | 250 |
| 2012 | 124 | 241 |
| 2013 | 137 | 311 |
| 2014 | 231 | 408 |
| 2015 | 253 | 453 |
| 2016 | 306 | 543 |
| 2017 | 303 | 524 |
| 2018 | 374 | 489 |
| 2019 | 342 | 597 |
| 2020 | 353 | 649 |
| 2021 | 381 | 773 |
| 2022 | 355 | 844 |
| 2023 | 386 | 909 |
| 2024 | 439 | 991 |
| 2025 | 445 | 875 |
| 2026 | 326 | 626 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 47/55The modifying agent being also a pharmacologically or therapeutically active agent, i.e.1,381
- A61K 47/549Sugars, nucleosides, nucleotides or nucleic acids1,365
- A61K 47/542Carboxylic acids1,189
- A61K 47/543Lipids1,158
- A61K 47/545Heterocyclic compounds1,156
- A61K 47/554The modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or458
- A61K 47/555Pre-targeting systems involving an organic compound, other than a peptide, protein or361
- A61K 47/547Chelates308
Recent patents
- Pharmaceutical composition containing anionic drug, and preparation method therefor6 Oct 2026US 12,752,010 B2Samyang Holdings Corporation
- Benzoheterocycle substituted tetrahydroisoquinoline compound6 Oct 2026US 12,752,011 B2Jiangxi Jemincare Group Co., Ltd
- EGFR degraders and associated methods of use6 Oct 2026US 12,752,012 B2BeOne Medicines | GmbH
- Near-infrared dyes and conjugates for targeting tumors6 Oct 2026US 12,752,023 B2Lahjavida, LLC
- Glucose triptolide conjugates and uses thereof6 Oct 2026US 12,753,200 B2Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
- Microbiome-based GABA Cream with Chondroitin Sulfate Transdermal Delivery System8 Oct 2026US 2026/0306531 A1
- Nanoparticles for photoimmune therapy comprising photosensitizer and adjuvant, and usage thereof8 Oct 2026US 2026/0306632 A1Korea Institute of Science and Technology
- A combination therapy for cancer treatment8 Oct 2026US 2026/0306633 A1Purdue Research Foundation
- Pharmaceutical compositions comprising bupropion and cysteine8 Oct 2026US 2026/0306637 A1Antecip Bioventures II LLC
- Compounds and uses thereof8 Oct 2026US 2026/0306638 A1Foghorn Therapeutics Inc.
Most cited
By later US patents
- Uncharged morpholino-based polymers having achiral intersubunit linkages1,700US 5,034,506 AAnti-Gene Development Group · 1991
- Backbone modified oligonucleotide analogs983US 5,602,240 ACiba-Geigy Corporation · 1997
- Alpha-morpholino ribonucleoside derivatives and polymers thereof900US 5,235,033 AAnti-Gene Development Group · 1993
- Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages851US 5,185,444 AAnti-Gene Deveopment Group · 1993
- Sequence-specific binding polymers for duplex nucleic acids786US 5,166,315 AAnti-Gene Development Group · 1992